Minapharm Pharmaceuticals (CAI:MIPH) Debt-to-EBITDA : N/A (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:MIPH Minapharm Pharmaceuticals CAI:MIPH
49 GF Score
Price E£809.00
GF Value E£374.15
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Minapharm Pharmaceuticals Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Minapharm Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2025 was E£2,682 Mil. Minapharm Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2025 was E£2,206 Mil. Minapharm Pharmaceuticals's annualized EBITDA for the quarter that ended in Sep. 2025 was E£1,159 Mil. Minapharm Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2025 was 4.22.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Minapharm Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

CAI:MIPH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.54   Med: 3.37   Max: 7.88
Current: 3.37

During the past 4 years, the highest Debt-to-EBITDA Ratio of Minapharm Pharmaceuticals was 7.88. The lowest was 1.54. And the median was 3.37.

CAI:MIPH's Debt-to-EBITDA is ranked worse than
71.24% of 678 companies
in the Drug Manufacturers industry
Industry Median: 1.64 vs CAI:MIPH: 3.37

Minapharm Pharmaceuticals  (CAI:MIPH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Minapharm Pharmaceuticals Debt-to-EBITDA Related Terms

Minapharm Pharmaceuticals Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Minapharm Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minapharm Pharmaceuticals Debt-to-EBITDA Chart

Minapharm Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
1.56 2.27 7.93 4.73

Minapharm Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Jun25 Sep25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.67 7.60 4.35 N/A N/A

CAI:MIPH vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Minapharm Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Minapharm Pharmaceuticals's Debt-to-EBITDA falls into.


CAI:MIPH
49GF Score
Minapharm Pharmaceuticals CAI:MIPH
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minapharm Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Minapharm Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2644.151947 + 2249.760479) / 1154.459712
=4.24

Minapharm Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2682.042398 + 2206.4989) / 1158.731572
=4.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2025) EBITDA data.

Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?

Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued. The current stock price of E£809.00 is trading 116.2% above its estimated GF Value™ of E£374.15. GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CAI:MIPH:

  • Debt-to-EBITDA: N/A
  • GF Value™: E£374.15 vs. price of E£809.00 (116.2% above fair value)
  • GF Score™: 49/100 with 10 warning signs

No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Minapharm Pharmaceuticals Business Description

Address El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
49GF Score

Get the complete analysis for CAI:MIPH

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£809.00
Price
E£374.15
GF Value